Summary
Northwest Biotherapeutics, Inc. (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer in an effective way without the side effects that are associated with the normal chemotherapy drugs. Using its proprietary technology platform, DCVax, the company developed a robust pipeline of therapeutic product candidates. DCVax is a personalized immune therapy and consists of therapeutic vaccine which uses patient’s own dendritic cells as the therapeutic agent. The product has two components, namely, dendritic cells (immune cells) and antigens (cancer biomarkers). The company’s product lines include DCVax-L, for the treatment of glioblastoma multiforme (GBM) brain cancer (Phase III) and metastatic ovarian cancer (Phase I completed); DCVax-Direct, for the treatment of all solid tumor cancers (Phase I/II underway) and colon cancer metastases (Phase I/II planned); and DCVax-Prostate, for the treatment of late stage prostate cancer (Phase III approved by FDA). NW Bio is headquartered in Bethesda, Maryland, the US.
Northwest Biotherapeutics, Inc. (NWBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Northwest Biotherapeutics, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 12
Equity Offering 12
Northwest Biotherapeutics to Raise USD27.6 Million in Private Placement of Shares 12
Northwest Biotherapeutics Raises USD12.6 Million in Private Placement of Shares 14
Northwest Biotherapeutics to Raise USD30 Million in Private Placement of Shares 16
Northwest Biotherapeutics Raises USD40 Million in Private Placement of Shares 18
Northwest Biotherapeutics Raises USD25 Million in Private Placement of Shares 19
Northwest Biotherapeutics Raises USD11.5 Million in Private Placement of Shares 21
Northwest Biotherapeutics Completes Private Placement Of Shares For US$15 Million 23
Northwest Biotherapeutics Completes Public Offering Of Units For US$27 Million 25
Northwest Biotherapeutics Completes Private Placement Of Units For US$15 Million 27
Northwest Biotherapeutics Completes Private Placement Of Shares For US$10 Million 29
Northwest Biotherapeutics Completes Public Offering Of Shares For US$14 Million 30
Northwest Biotherapeutics Completes Private Placement Of Shares For US$5 Million 32
Northwest Biotherapeutics Announces Private Placement Of Shares For US$3 Million 33
Northwest Biotherapeutics Completes Private Placement Of US$2.65 Million 35
Debt Offering 36
Northwest Biotherapeutics Raises USD17.5 Million in Private Placement of 5% Notes Due 2017 36
Northwest Biotherapeutics Completes Private Placement Of Convertible Notes For US$3 Million 37
Northwest Biotherapeutics, Inc. - Key Competitors 38
Key Employees 39
Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Tables
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Northwest Biotherapeutics, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Northwest Biotherapeutics, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Northwest Biotherapeutics to Raise USD27.6 Million in Private Placement of Shares 12
Northwest Biotherapeutics Raises USD12.6 Million in Private Placement of Shares 14
Northwest Biotherapeutics to Raise USD30 Million in Private Placement of Shares 16
Northwest Biotherapeutics Raises USD40 Million in Private Placement of Shares 18
Northwest Biotherapeutics Raises USD25 Million in Private Placement of Shares 19
Northwest Biotherapeutics Raises USD11.5 Million in Private Placement of Shares 21
Northwest Biotherapeutics Completes Private Placement Of Shares For US$15 Million 23
Northwest Biotherapeutics Completes Public Offering Of Units For US$27 Million 25
Northwest Biotherapeutics Completes Private Placement Of Units For US$15 Million 27
Northwest Biotherapeutics Completes Private Placement Of Shares For US$10 Million 29
Northwest Biotherapeutics Completes Public Offering Of Shares For US$14 Million 30
Northwest Biotherapeutics Completes Private Placement Of Shares For US$5 Million 32
Northwest Biotherapeutics Announces Private Placement Of Shares For US$3 Million 33
Northwest Biotherapeutics Completes Private Placement Of US$2.65 Million 35
Northwest Biotherapeutics Raises USD17.5 Million in Private Placement of 5% Notes Due 2017 36
Northwest Biotherapeutics Completes Private Placement Of Convertible Notes For US$3 Million 37
Northwest Biotherapeutics, Inc., Key Competitors 38
Northwest Biotherapeutics, Inc., Key Employees 39
Northwest Biotherapeutics, Inc., Subsidiaries 40
List of Figures
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Northwest Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Northwest Biotherapeutics, Inc., Medical Devices Deals, 2010 to YTD 2016 9
